Cited by 27Heart Failure Treatment and ManagementHeart rate and cardiovascular healthAtrial Fibrillation Management and Outcomes

Mortality and morbidity of heart failure treated with digoxin. A propensity-matched study: Digoxin and heart failure

Open access
Andrey, J. L., Romero, S., García-Egido, A., Escobar, M. A., Corzo, R., Garcia-Dominguez, G., Lechuga, V., Gómez, F.·2011·International Journal of Clinical Practice

Abstract

BACKGROUND: The role of digoxin in the prognosis of patients with heart failure (HF) remains unclear. AIMS: To evaluate the relationship of commencing treatment with digoxin (CTDig) with the mortality and the morbidity of patients with HF. METHODS: Prospective study over 8 years on 4467 patients with HF. Main outcomes were all-cause and cardiovascular mortality, hospitalisations and visits. We analyse the independent relationship of CTDig, with the mortality and the morbidity, stratifying patients for cardiovascular comorbidity, after propensity score-matching for potential confounders (1421 patients who CTDig vs. another 1421 patients non-exposed to digoxin). RESULTS: During a median follow up of 46.1 months, 1872 patients (65.9%) died, and 2203 (77.5%) were hospitalised. CTDig was associated with a lower all-cause mortality (HR = 0.90 [95% CI, 0.84-0.97]), and cardiovascular mortality (HR = 0.87 [0.81-0.96]), hospitalisation (HR = 0.91 [0.86-0.97]), 30-day readmission for HF (HR = 0.88 [0.79-0.95]), and visits (HR = 0.94 [0.90-0.98]) (p < 0.001 in all cases), after adjustment for the propensity to take digoxin, other medications, and other potential confounders. These effects of digoxin were independent of gender, or type of HF (systolic or non-systolic). CONCLUSION: The data suggest that therapy with digoxin is associated with an improved mortality and morbidity of HF, including women and patients with non-systolic HF.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1742-1241.2011.02771.x

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • The association between digoxin use and excess mortality in AF patients is likely due to selection and prescription biases rather than harm caused by digoxin, particularly as digoxin is commonly prescribed to sicker patients.

    “Observational studies have associated digoxin use with excess mortality in AF patients, [547][548][549] but this association is likely due to selection and prescription biases rather than harm caused by digoxin, [550][551][552][553] particularly as digoxin is commonly prescribed to sicker patients.225”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 1

  1. LeJemtel TH, Sonnenblick EH, Frishman WH. Diagnosis and management of heart failure. In: Fus- ter V, Alexander RW, O'Rourke RA, eds. Hurst's The Heart. 10th edn. New York, NY: McGraw-Hill, 2001: 778-807.

Cited by

Sorted by citations

Authors
Andrey, J. L., Romero, S., García-Egido, A., Escobar, M. A., Corzo, R., Garcia-Dominguez, G., Lechuga, V., & Gómez, F.
Affiliations
Universidad de Cádiz (ES)
Venue
International Journal of Clinical Practice
Published
2011-11-17
Volume
65
Issue
12
Pages
1250-1258
ISSN
1368-5031 (ISSN-L)
OpenAlex
W1491928200
Cited by
27
References
29
Citations by year
2026: 1 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 4 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 1 · 2016: 4 · 2015: 2 · 2014: 2 · 2013: 1 · 2012: 2
FWCI
1.32
Type
journal article
Language
en
Open access
Locations
  • International Journal of Clinical Practice (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Keywords
digoxin, heart failure, all-cause mortality, cardiovascular mortality, hospitalization, heart failure readmission, morbidity, women
MeSH terms
Aged, Cardiotonic Agents, Digoxin, Female, Heart Failure, Humans, Male, Prospective Studies, Treatment Outcome, Kaplan-Meier Estimate, Propensity Score

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review